In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 71 to 80 of 437

Sort by

Type: GuidanceRemove Type: Guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [ID6352]	Technology appraisal guidance	TBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]	Technology appraisal guidance	TBC
Capsule sponge tests for detection of Barrett's oesophagus and oesophageal cancer (provisional title)	Health technology evaluation	TBC
Cardiometabolic disease prevention and treatment guidelines	NICE guideline	TBC
CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)	Health technology evaluation	TBC
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]	Technology appraisal guidance	30 September 2026
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]	Technology appraisal guidance	TBC
Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]	Technology appraisal guidance	TBC
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901) [ID6610]	Technology appraisal guidance	3 September 2026
Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]	Technology appraisal guidance	TBC

Results per page

10
25
50
All